UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) – Pfizer’s breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain’s state-run health service, the country’s healthcare cost-effectiveness watchdog said on Friday.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *